ArticleGenes & development1998
Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo.
Article in Genes & development, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 217 citations in OpenAlex.
- Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation.Cell death & disease · 2023Review
- A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1-CDK4 interaction.Breast cancer research and treatment · 2023Article
- Article
- Cyclin-dependent kinase 4 expression alters the number of keratinocyte stem cells in the mouse hair follicle.Cell biology international · 2022Article
- Oh, the Mutations You'll Acquire! A Systematic Overview of Cutaneous Squamous Cell Carcinoma.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2021Review
- The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy.International journal of molecular sciences · 2021Review
- Cell Proliferation and Tumor Induction by Ochratoxin A in Mouse Skin and Evaluation of Cyclin D1 and Cyclooxygenase-2 Expressions.Computational and mathematical methods in medicine · 2021Article
- The membrane-associated form of cyclin D1 enhances cellular invasion.Oncogenesis · 2020Article
- Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.Expert review of anticancer therapy · 2019Review
- cAMP-mediated regulation of melanocyte genomic instability: A melanoma-preventive strategy.Advances in protein chemistry and structural biology · 2019Review
- Enhancement of Cutaneous Wound Healing by Dsg2 Augmentation of uPAR Secretion.The Journal of investigative dermatology · 2018Article
- ETS-targeted therapy: can it substitute for MEK inhibitors?Clinical and translational medicine · 2017Review
- Characterization of hair-follicle side population cells in mouse epidermis and skin tumors.Oncology letters · 2017Article
- Cyclin D3 deficiency inhibits skin tumor development, but does not affect normal keratinocyte proliferation.Oncology letters · 2017Article
- Cell cycle proteins as promising targets in cancer therapy.Nature reviews. Cancer · 2017Review
- Cyclin D1 Promotes Androgen-Dependent DNA Damage Repair in Prostate Cancer Cells.Cancer research · 2016Article
- Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.Oncotarget · 2015Article
- Modeling cutaneous squamous carcinoma development in the mouse.Cold Spring Harbor perspectives in medicine · 2014Review
- Article
- NFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation.Cellular signalling · 2013Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Cyclin D1 is part of a cell cycle control node consistently deregulated in most human cancers. However, studies with cyclin D1-null mice indicate that it is dispensable for normal mouse development as well as cell growth in culture. Here, we provide evidence that ras-mediated tumorigenesis depends on signaling pathways that act preferentially through cyclin D1. Cyclin D1 expression and the activity of its associated kinase are up-regulated in keratinocytes in response to oncogenic ras. Furthermore, cyclin D1 deficiency results in up to an 80% decrease in the development of squamous tumors generated through either grafting of retroviral ras-transduced keratinocytes, phorbol ester treatment of ras transgenic mice, or two-stage carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.